Matthew Pezda, MD
Ophthalmology · Las Vegas, NVNPI 1154560951
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.6%), food and beverage and gifts — rather than concentrated in one kind of arrangement. AbbVie accounts for 65.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $1,816 and has fallen 94.5% since, to $99 in 2025.
Across 25 payments — averaging $109.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alcon$394
- Regeneron Healthcare Solutions, Inc.$165
- Genentech USA, Inc.$116
- Regeneron$103
- Bausch & Lomb Americas Inc.$53
- plus $119 from 4 others
Across 19 payments — averaging $7004.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$133K
What the payments were for
- Consulting fees$1,60059%
- Food & beverage$65924%
- Education$602%
- Gifts$39414%
- Entertainment$191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 7 | $1,783 |
| Alcon | 1 | $394 |
| Regeneron Healthcare Solutions, Inc. | 6 | $165 |
| Genentech USA, Inc. | 3 | $116 |
| Regeneron | 1 | $103 |
| Bausch & Lomb Americas Inc. | 2 | $53 |
| Apellis Pharmaceuticals, Inc. | 2 | $43 |
| Oculus Surgical Inc. | 1 | $34 |
| Biogen | 1 | $23 |
| Optos, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$1,600
- Constellation$394
- EYLEA$103
How this compares
$2,732 in reported general payments places this provider in the 60th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 126 | $4,570 |
| Ketorolac Tromethamine | 90 | $1,855 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Las Vegas
- Eva LiangLas Vegas$496K
- Steven LeibowitzLas Vegas$147K
- Wonchon LinLas Vegas$43K
- Ravindranath ReddyLas Vegas$30K
- Emily SchorrLas Vegas$17K
- Frank LeeLas Vegas$12K
- Tigran KostanyanLas Vegas$11K
- Tushina ReddyLas Vegas$11K
- Kent WellishLas Vegas$10K
- Eissa HannaLas Vegas$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.